Here we show that in colon cancer cells, despite identical downstream SMAD signaling, activin and TGFβ have opposing effects on the cdk2 inhibitor p21 resulting in distinct regulations of each pathway. This evidence concerns the gene CDK2 and malignant colon neoplasm.